Biotechnology

A new partnership will embed real-world cell therapy manufacturing into NJIT's graduate program, aiming to fill a critical skills gap in the biotech industry.

Tanabe Pharma Canada's 'Letters to ALS' offers a raw, intimate look into the fight against the disease, strengthening community bonds through shared stories.

A key recommendation for the drug BIMZELX could soon give Quebec patients a powerful new weapon against the debilitating skin disease hidradenitis suppurativa.

A novel three-in-one antibody from CStone shows a 90% response rate in lung cancer and potent activity in 'cold tumors,' heralding a new era for immunotherapy.

PetaSight's acquisition of Babbage Insight aims to fix a broken system with an 'intelligent OS', tackling the 38% data discard rate in life sciences PMR.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

A new partnership between Boehringer Ingelheim and the CT Science Center seeks to build a talent pipeline for the state's booming biopharma industry.

Armata Pharmaceuticals posts a staggering $174M annual loss, triggering a 'going concern' alert, yet its promising phage therapy pipeline advances.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.

Growth equity firm SEMCAP launches a new fund with Unilever Prestige visionary Vasiliki Petrou, targeting the booming wellness and longevity market.

Early data for VG801 shows vision improvement in Stargardt disease patients, leveraging novel tech and fast-track FDA support to tackle a leading cause of blindness.

A potential first-ever treatment for a severe rare skin disease gets a major boost from the FDA, accelerating its path to patients and exciting investors.

Enlivex reported a staggering $1.23 billion profit, not from its labs, but from a risky treasury of crypto assets. Is this genius or a gamble?

Riding high on record 2025 results and a new FDA approval, LivaNova faces intense scrutiny ahead of its May 6 earnings call. Can it sustain the momentum?

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

New data reveals Otsuka's VOYXACT clears key markers of kidney damage in IgA nephropathy, offering new hope beyond symptom management for patients.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

Following a 40-year career shaping biotech finance, Jessica Chutter's move to PTC's board signals major strategic ambitions for the rare disease firm.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.